Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 14, 2026DiagnosticsOpen Access

68Ga-FAPI-04 PET/CT in the Diagnosis of Hepatocellular Carcinoma Associated with Cirrhosis: Diagnostic Value, Correlation Between PET Parameters of the Tumor and Its Size, and PIVKA-II Levels

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZhamilya ZholdybayKazakh National Medical UniversityZZZhanar ZhakenovaKazakh National Medical UniversityBIB K IssamatovKazakh National Medical University

Discussion

Loading...

Member takes

Implication

Prospective study assesses 68Ga-FAPI-04 PET/CT's effectiveness in diagnosing HCC, suggesting it complements traditional imaging.

Key Points

  • The study aimed to evaluate the diagnostic performance of 68Ga-FAPI-04 PET/CT in detecting hepatocellular carcinoma (HCC) in patients with and without cirrhosis.
  • Conducted a prospective single-center study with 59 HCC patients (37 with cirrhosis, 22 without).
  • Administered 68Ga-FAPI-04 PET/CT following standard dosing.
  • Calculated semi-quantitative parameters including SUVmax, SUVmean, and tumor-to-background ratio.
  • Utilized histopathology and multimodal imaging for diagnostic performance assessment.
  • Performed statistical analyses using the Mann–Whitney U test and Spearman correlation.
  • Overall sensitivity for HCC detection was 89.8%, with specificity at 60% and accuracy of 87%.
  • Sensitivity and specificity were lower in cirrhotic patients due to higher liver background uptake.
  • Strong correlation between SUVmax and tumor size in non-cirrhotic HCC patients.
  • Moderate association between SUVmax and PIVKA-II levels in cirrhotic patients.

Cite This Study

Zholdybay et al. (2026) studied this question.

synapsesocial.com/papers/6967196bc0d1e3cfbfce8c46https://doi.org/10.3390/diagnostics16020249
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 168 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer2019 · 1,509 citations
  2. 2Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma2021 · 173 citations
  3. 3Variant Hepatocellular Carcinoma Subtypes According to the 2019 WHO Classification: An Imaging-Focused Review2022 · 59 citations
  4. 4PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma2021 · 194 citations
  5. 5FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease2023 · 369 citations